Diffuse glioma perfusion quantification with ASL and DSC: a head-to-head comparison with 15O-H2O PET
Frontiers in Oncology · 05.08.2026 · 16
DOI: 10.3389/fonc.2026.1766519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 05.08.2026. Verfasst von Jan Petr und 10 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and purpose Arterial spin labeling (ASL) is a non-invasive alternative to dynamic susceptibility contrast (DSC) for measuring cerebral blood flow (CBF), even though both methods measure slightly different contrast. This study compares ASL and DSC MRI with the gold-standard measurement 15 O-H 2 O PET in gliomas.
Methods
Eight patients (age 40.5 ± 17.0 years, 3 women) with grade 2–4 gliomas were scanned at 3T MRI with ASL and DSC, and at PET using a 15 O-H 2 O PET tracer. Quantitative comparison was performed in contralateral normal-appearing tissue, and in tumors with and without normalization to contralateral tissue. The mean voxel-wise relative error (MRE) was calculated for PET-ASL and PET-DSC. The MRE difference between ASL and DSC was evaluated using a t-test (p < 0.05 after Bonferroni correction).
Results
ASL showed superior (p<0.001) voxel-wise agreement with PET (MRE 26.8%) in the normal-appearing tissue compared with DSC (MRE 33.8%). While the tumor maximum CBF normalized to contralateral gray matter comparison with PET did not differ between (p=0.5) ASL (MRE 23.2%) and DSC (MRE 22.0%), voxel-wise agreement was better (p<0.001) for ASL (MRE 27.2%) than for DSC (MRE 35.0%). Visually, ASL overestimated CBF near larger arteries, and DSC underestimated CBF in non-enhancing tumors with tiny capillaries.
Conclusion
While neither ASL nor DSC is fully comparable to 15 O-H 2 O PET in all tumors, ASL presents a viable non-invasive alternative to DSC for glioma imaging. These findings encourage future studies to investigate the extent to which the combination of ASL and DSC can measure complementary tumor hemodynamics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
- Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, Netherlands.
- Brain Tumor Center Amsterdam, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, Netherlands.
- Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, Netherlands.
- Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, United Kingdom.
Zitieren
APA
Petr, J., Verburg, N., Kuijer, J. P. A., Koopman, T., Keil, V. C., Warnert, E. A. H., Barkhof, F., van den Hoff, J., Boellaard, R., De Witt Hamer, P. C., & Mutsaerts, H. J. M. M. (2026). Diffuse glioma perfusion quantification with ASL and DSC: a head-to-head comparison with 15O-H2O PET. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1766519
Vancouver
Petr J, Verburg N, Kuijer JPA, Koopman T, Keil VC, Warnert EAH, et al. Diffuse glioma perfusion quantification with ASL and DSC: a head-to-head comparison with 15O-H2O PET. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1766519
BibTeX
@article{Petr2026,
author = {Petr, Jan and Verburg, Niels and Kuijer, Joost P A and Koopman, Thomas and Keil, Vera C and Warnert, Esther A H and Barkhof, Frederik and van den Hoff, Joerg and Boellaard, Ronald and De Witt Hamer, Philip C and Mutsaerts, Henk J M M},
title = {Diffuse glioma perfusion quantification with ASL and DSC: a head-to-head comparison with 15O-H2O PET},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1766519}
}
EUVIMED